Merck KgaA Invests $48.5 Million in Life Science Manufacturing Expansion in US
December 07 2020 - 9:01AM
Dow Jones News
By Cecilia Butini
Merck KgaA said Monday that it is investing 40 million euros
($48.5 million) in the expansion of its life science manufacturing
capacity in the U.S.
The German pharmaceuticals and chemicals company said the
expansion is set to increase capacity and output at its
Massachusetts and New Hampshire sites by the end of 2021 and 2022,
respectively. As a result of the expansion, nearly 700 new
manufacturing positions will be created, Merck said.
The Massachusetts site, located in Danvers, will lead to the
creation of about 400 jobs throughout 2021 with an investment of
about EUR21 million, according to Merck. The New Hampshire plant,
located in Jaffrey, will see a workforce increase of 275 roles by
2022, with an investment of about EUR18.5 million.
The sites focus on manufacture of products for lifesaving
therapies, including Covid-19 vaccines, and on providing products
and services for biopharmaceutical manufacturing, Merck said. The
expansion plan for the two U.S. sites is part of previously
announced investments in the life sciences business totalling more
than EUR350 million.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
December 07, 2020 08:46 ET (13:46 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2024 to May 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From May 2023 to May 2024
